Financial Contrast: MEDNAX (MD) and Its Competitors

MEDNAX (NYSE: MD) is one of 44 public companies in the “Healthcare Facilities & Services” industry, but how does it weigh in compared to its rivals? We will compare MEDNAX to related companies based on the strength of its profitability, valuation, earnings, analyst recommendations, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for MEDNAX and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MEDNAX 1 8 2 0 2.09
MEDNAX Competitors 206 1383 1916 35 2.50

MEDNAX currently has a consensus target price of $54.50, indicating a potential upside of 17.66%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 2.60%. Given MEDNAX’s higher probable upside, equities analysts plainly believe MEDNAX is more favorable than its rivals.

Profitability

This table compares MEDNAX and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MEDNAX 7.76% 10.80% 5.57%
MEDNAX Competitors 12.42% 0.45% 1.36%

Earnings & Valuation

This table compares MEDNAX and its rivals revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
MEDNAX $3.18 billion $324.91 million 16.37
MEDNAX Competitors $6.37 billion $198.65 million 348.04

MEDNAX’s rivals have higher revenue, but lower earnings than MEDNAX. MEDNAX is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

96.3% of MEDNAX shares are held by institutional investors. Comparatively, 75.6% of shares of all “Healthcare Facilities & Services” companies are held by institutional investors. 2.4% of MEDNAX shares are held by insiders. Comparatively, 13.4% of shares of all “Healthcare Facilities & Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

MEDNAX has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, MEDNAX’s rivals have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.

Summary

MEDNAX rivals beat MEDNAX on 8 of the 13 factors compared.

About MEDNAX

MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply